Stock 688468 CHEMCLIN DIAGNOSTICS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Chemclin Diagnostics Co., Ltd.

Equities

688468

CNE100005311

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 27/05/2024 BST 		5-day change 1st Jan Change
7.26 CNY -0.82% Intraday chart for Chemclin Diagnostics Co., Ltd. -2.55% -32.72%
05-21 Shareholders to Cut Up to 2% Stake in Chemclin Diagnostics MT
05-03 Chemclin Diagnostics Launches Homegrown Immunodetection Kits MT

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 7,186 3,797 4,327
Enterprise Value (EV) 1 6,286 2,825 3,643
P/E ratio 48.4 x 24.9 x 29.2 x
Yield 0.95% 3.66% 1.16%
Capitalization / Revenue 15.3 x 8.16 x 9.72 x
EV / Revenue 13.4 x 6.07 x 8.18 x
EV / EBITDA 35 x 16.2 x 21.6 x
EV / FCF 109 x 30.3 x -21.5 x
FCF Yield 0.91% 3.3% -4.66%
Price to Book 5.62 x 2.75 x 3.12 x
Nbr of stocks (in thousands) 401,000 401,000 401,000
Reference price 2 17.92 9.470 10.79
Announcement Date 27/04/22 27/04/23 29/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 454.7 418.2 470.8 465.3 445.3
EBITDA 1 182.7 156.1 179.7 174.8 168.3
EBIT 1 141.3 114.1 137.1 135.1 131.5
Operating Margin 31.07% 27.28% 29.13% 29.04% 29.53%
Earnings before Tax (EBT) 1 159.6 135.4 162.2 177.4 166.1
Net income 1 140.6 117 142.8 152.6 147.4
Net margin 30.92% 27.98% 30.32% 32.8% 33.09%
EPS 2 0.7000 0.3300 0.3700 0.3800 0.3700
Free Cash Flow 1 93.9 6.059 57.47 93.29 -169.6
FCF margin 20.65% 1.45% 12.21% 20.05% -38.08%
FCF Conversion (EBITDA) 51.39% 3.88% 31.99% 53.37% -
FCF Conversion (Net income) 66.79% 5.18% 40.26% 61.12% -
Dividend per Share 2 0.2778 - 0.1700 0.3470 0.1250
Announcement Date 18/03/21 18/03/21 27/04/22 27/04/23 29/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 - - - - -
Net Cash position 1 583 553 900 973 684
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 93.9 6.06 57.5 93.3 -170
ROE (net income / shareholders' equity) 17.1% 13.3% 13.2% 11.5% 10.6%
ROA (Net income/ Total Assets) 9.55% 7.13% 7.03% 5.59% 4.82%
Assets 1 1,473 1,641 2,030 2,731 3,059
Book Value Per Share 2 2.410 2.460 3.190 3.440 3.460
Cash Flow per Share 2 0.2900 0.6200 0.7800 0.8500 1.120
Capex 1 55.2 83.3 72.5 125 301
Capex / Sales 12.15% 19.92% 15.41% 26.93% 67.67%
Announcement Date 18/03/21 18/03/21 27/04/22 27/04/23 29/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Diagnostic & Testing Substances

1st Jan change Capi.
CHEMCLIN DIAGNOSTICS CO., LTD. Stock Chemclin Diagnostics Co., Ltd.
-32.72% 396M
BIOMÉRIEUX Stock bioMérieux
-6.61% 12.1B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-4.07% 8.14B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+6.84% 5.72B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+28.13% 5.51B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-59.44% 2.72B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+8.04% 2.59B
VITROLIFE AB Stock Vitrolife AB
-7.55% 2.34B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+21.84% 2.11B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-8.15% 1.79B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. 688468 Stock
  4. Financials Chemclin Diagnostics Co., Ltd.